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INTRODUCTION
Abbou, et al. first performed robot-assisted radical prostatec-
tomy (RARP) in 2000.1 Since then, the da Vinci Surgical System 
(Intuitive Surgical, Sunnyvale, CA, USA) has been used in South 
Korea to conduct various types of urological surgery including 
radical prostatectomy, partial nephrectomy, and radical cys-
tectomy, beginning in 2005.2 Radical prostatectomy is consid-
ered the gold standard of surgical treatment.3 However, the 
demand for RARP has increased due to better defined surgical 
anatomy and improved surgical maneuverability.2 Thirty-six da 
Vinci robotic surgery platforms are currently in use through-
out 30 hospitals in Korea. A total of 24207 (24337 cases) patients 
underwent robotic surgery from 2005 to 2012, and the average 
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Purpose: To systematically update evidence on the clinical efficacy and safety of robot-assisted radical prostatectomy (RARP) ver-
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and others, were searched, collecting data from January 1980 to August 2013. The quality of selected systematic reviews was assessed 
using the revised assessment of multiple systematic reviews and the modified Cochrane Risk of Bias tool for non-randomized studies.
Results: A total of 61 studies were included, including 38 from two previous systematic reviews rated as best available evidence and 
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was lower for RARP than for RRP. Among functional outcomes, the risk of urinary incontinence was lower and potency rate was signifi-
cantly higher for RARP than for RRP. Regarding oncologic outcomes, positive margin rates were comparable between groups, and 
although biochemical recurrence (BCR) rates were lower for RARP than for RRP, recurrence-free survival was similar after long-term 
follow up.
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and selective reporting biases with longer-term follow-up are needed to determine the clinical efficacy and safety of RARP.
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annual growth rate for robotic surgery was 51.4% from 2005 to 
2011. One-third (33.7%) of all robotic surgeries in the world 
were RARP; this was the most commonly performed robotic 
procedure.4
In 2013, the Korean government announced plans to radi-
cally enhance health insurance coverage for major conditions 
including cancer. Robotic surgery to treat prostatic cancer was 
to be included in the discretionary benefits list by as early as 
2015.5 However, its inclusion has been questioned by some, 
since the comparative effectiveness of robotic surgery re-
mains unclear. In previous reviews of RARP versus retropubic 
radical prostatectomy (RRP), RARP yielded better peri-opera-
tive outcomes.6,7 However, the evidence suggesting that RARP 
is associated with a decrease in urinary incontinence, improved 
potency, and reduction in biochemical recurrence (BCR), com-
pared to RRP is limited. This is because most publications had 
a high risk of bias and exhibited extensive patient heterogene-
ity. While some experts have argued that the extension of dis-
cretionary benefits to robotic surgery increases patient choice, 
others point out that, without scientific evaluation, expansion 
of coverage will undermine the National Health Insurance sys-
tem because demand will explode.8
Accordingly, the aim of the present paper was to compre-
hensively review and update data on the efficacy and safety of 
RARP versus RRP in patients with prostate cancer. 
MATERIALS AND METHODS
Inclusion criteria
Studies eligible for inclusion consisted of randomized con-
trolled trials and prospective and retrospective cohort studies 
that compared RARP and RRP. A study was excluded if it did 
not report any outcome of interest (i.e., safety or functional and 
oncological outcomes).
Search strategy 
We systematically reviewed recent research using techniques 
that evaluated comparative effectiveness, as suggested by the 
Agency for Healthcare Research and Quality.9
Existing systematic reviews and health technology assess-
ment reports were identified by searching ovidMEDLINE, 
ovidEMBASE, the Cochrane Library, KoreaMed, RISS4U, KISS, 
KISTI, KMbase, and NDSL from January 1980 to August 2013. 
We used combinations of MeSH terms and the following 
phrases: exp Prostatic Neoplasms/or prostatic cancer, exp Ro-
botics/or exp Surgery; and Computer-Assisted/or robot*/or (da 
vinci or davinci) (Supplementary Table 1, only online). In ad-
dition, we scanned the reference lists of relevant reviews and 
reports by international health technology assessment agen-
cies to ensure comprehensive data collection. We then searched 
for recent studies (published from January 2010 to September 
2013), because two high-quality systematic reviews (HIQA10; 
Ramsay, et al.11) had only searched primary studies up to March 
2011. We did not restrict publication language.
Two authors independently reviewed all titles and abstracts 
and retrieved full-texts of all studies potentially meeting inclu-
sion criteria. If the reviewing authors disagreed, the conflict 
was resolved by discussion and consensus, or by consulting a 
third member of the review team. We used structured data ex-
traction forms to gather pertinent information; this included 
characteristics of the country of publication, study design, study 
participants, interventions, comparisons, outcome measures, 
outcome definitions, follow-up durations, and results that were 
statistically significant. If information was unclear or missing, 
we contacted the original authors by e-mail.
Quality assessment and data synthesis 
Two reviewers independently assessed the risk of bias. System-
atic reviews were evaluated using the Revised Assessment of 
Multiple Systematic Reviews (R-AMSTAR) tool,12 and non-ran-
domized studies newly published after 2010 were evaluated 
using the modified Cochrane Risk of Bias tool.11 The modified 
RoB tool is composed of seven specific domains: random se-
quence generation (selection bias), allocation concealment 
(selection bias), controlling for confounding (selection bias), 
blinding (performance and detection bias), incomplete out-
come data (attrition bias), selective outcome reporting (report-
ing bias), and other sources of bias (regarding funding source). 
Any disagreement was resolved by discussion. 
Meta-analysis was performed using Revman 5.2 and Com-
prehensive Meta-Analysis (CMA) version 2.0. For continuous 
outcomes, weighted mean differences or standardized mean 
difference and 95% confidence intervals (CIs) were calculated 
using the random-effects model of the Dersimonian-Laird 
method.13 Mantel-Haenszel risk ratios (M-H RRs), with 95% 
CIs, derived using a random effects model, were calculated if 
outcomes were dichotomous.14 Heterogeneity was assessed 
using the I2 and Q statistics. An I2>50% was considered to indi-
cate substantial heterogeneity.15 With the Q statistic, heteroge-
neity was deemed to be significant if p<0.10. Publication bias 
was tested by Funnel plotting and using Egger’s test.16
RESULTS
Details of included studies
An overview of the study selection process is provided in Fig. 
1. We used two existing systematic reviews on RARP in pa-
tients with prostate cancer as the best-available evidence, which 
included 38 studies. An additional twenty-three studies were 
included through new searches for updates. Finally, we evalu-
ated 61 articles, none of which was a randomized controlled 
clinical trial (Supplementary Table 2, only online). In charac-
teristic of the included studies, the average age of the partici-
pants ranged from late fifties to sixties, which were similar be-
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tween the two procedures. Of the 61 studies, 14 reported sig-
nificantly different pre-operative prostate-specific antigen (PSA) 
levels. Also, 22.9% of the included studies reported significantly 
higher clinical stages for RRP patients than for RARP patients.
Quality assessment results
The summary of risk of bias in the cohort studies is shown in 
Fig. 2. In this evaluation, random sequence generation and 
concealment of allocation to group were considered to be im-
portant in terms of estimating any treatment effect. Most stud-
ies were flawed in this respect. Accordingly, most of the stud-
ies were susceptible to selection bias. Blinding domain was 
rated as a low risk of bias because of objective outcome mea-
sures or patient reported outcomes using valid and reliable 
questionnaires. In the selective outcome reporting domain, 
approximately 40% of the included studies were rated as hav-
ing a high or unclear risk of bias, because those studies did 
not investigate all of the outcomes of interest in this review.
Perioperative outcomes
Complications
There was no significant difference in the rates of anastomosis 
site leakage (eight studies with 4880 participants; RR 0.78, 95% 
CI 0.47–1.28; p=0.330), infection (six studies with 7373 partici-
pants; RR 0.37, 95% CI 0.09–1.54; p=0.770), ileus (six studies 
with 2437 participants; RR 0.82, 95% CI 0.41–1.66; p=0.580), or 
deep vein thrombosis (five studies with 4576 participants; RR 
0.75, 95% CI 0.39–1.46; p=0.400) between RARP and RRP in 
the selected studies (Supplementary Table 3, only online). How-
Fig. 1. Study selection flow-diagram.
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ever, RARP was associated with lower rates of bladder neck 
contracture (five studies with 2846 participants; RR 0.26, 95% 
CI 0.09–0.73; p=0.010), organ injury (ten studies with 6715 
participants; RR 0.54, 95% CI 0.30–0.99; p=0.040), and pulmo-
nary embolism (three studies with 3159 participants; RR 0.24, 
95% CI 0.07–0.83; p=0.002), compared to RRP (Supplementary 
Fig. 1A, B, and C, respectively, only online). Transfusion data 
were reported in 25 studies (10605 participants). Although 
high degrees of study heterogeneity were evident, RARP was 
associated with a lower risk of transfusion than RRP in both 
prospective (12 studies with 6038 participants; RR 0.19, 95% 
CI 0.11–0.30; p<0.001) and retrospective studies (13 studies 
with 4567 participants; RR 0.14, 95% CI 0.07–0.30; p<0.001) 
(Supplementary Fig. 1D, only online).
Clavien-Dindo classification
Data from 19 studies (12175 participants) indicated a slight, but 
significant, difference in Clavien-Dindo complication rates af-
ter RARP, compared to RRP (RR 0.37, 95% CI 0.25–0.55, I2= 
84%; p<0.001). When complications were classified by severi-
ty, Clavien-Dindo I–II scores (11 studies with 5295 partici-
pants) and Clavien-Dindo III–V (8 studies with 6880 partici-
pants) scores suggested that RARP was associated with a 
decreased risk of Clavien-Dindo scores of I–II (RR 0.27, 95% CI 
0.16–0.46, I2=88%; p<0.001) However, studies reporting such 
outcomes exhibited substantial heterogeneity (Supplementary 
Fig. 1E, only online).
Operation time 
RARP was associated with longer operating times than RRP 
(25 studies with 8080 participants; mean difference 32.27 min 
more; 95% CI: 12 to 52.54 min; p=0.002). Heterogeneity among 
study data was high (I2=98%) (Supplementary Fig. 1F, only online).
Length of stay 
Hospital days were reported in 27 studies (7939 participants). 
Sub-group analysis was carried out by classifying countries 
into the US, Asia-Pacific, and Europe. RARP was associated 
with shorter hospital stay in the US (13 studies with 5112 partic-
ipants; mean difference -0.66 days, 95% CI -1.19–-0.14; p= 
0.010), Asia-Pacific (five studies with 1256 participants; mean 
difference -3.39 days, 95% CI -4.11–-2.67; p<0.001), and Eu-
rope (nine studies with 1571 participants; mean difference 
-1.81 days, 95% CI -2.76–-0.86; p<0.001). Considerable hetero-
geneity was evident between studies (I2=99%), possibly attrib-
utable to differences in healthcare systems (Supplementary Fig. 
1G, only online).
Functional outcomes
Incontinence rate at 12 months
Based on the results of 11 studies (participants: 2510), RARP 
was associated with reduced urinary incontinence 12 months 
after surgery, compared to RRP (RR 0.62, 95% CI 0.42–0.93, I2= 
47%; p=0.020) (Fig. 3A). In order to consider differences in ba-
seline characteristics of participants, subgroup analysis was 
performed. In 10 studies with a similar pre-operative PSA lev-
el between groups, urinary incontinence rate at 1 year after sur-
gery was lower for RARP than for RRP (participants: 2214; RR 
0.66, 95% CI 0.45–0.99, I2=45%; p=0.040). Also, pre-operative 
clinical stage for all of the studies was not significantly differ-
ent between procedure groups.
Potency rate at 12 months
Based on the results of 10 studies (participants: 2142), RARP 
was found to be associated with improved postoperative po-
tency rate, compared to RRP (RR 1.41, 95% CI 1.18–1.70, I2= 
65%; p<0.001) (Fig. 3B). In addition, nine studies (participants: 
1956) with a similar pre-operative PSA level between groups 
demonstrated favorable potency rate for RARP (RR 1.41, 95% 
CI 1.16–1.72, I2=63%; p<0.001). In eight studies (participants: 
1965) with comparable pre-operative clinical stages between 
groups, RARP was associated with higher recovery of erectile 
function (RR 1.37, 95% CI 1.12–1.67, I2=69%; p=0.002). 
Oncological outcomes
Positive margin rates
Positive margin rates for RARP were equivalent to those for 
RRP in both prospective (13 studies, 6226 participants; RR 0.95, 
95% CI 0.74–1.23, I2=80%; p=0.72) and retrospective studies (23 
studies, 12813 participants; RR 0.88, 95% CI 0.75–1.03, I2=71%; 
p=0.110) (Fig. 4A). However, the heterogeneity among the re-
sults of individual studies was considerable. Sensitivity analy-
sis was performed with only low risk studies (seven studies with 
1412 participants; RR 0.93, 95% CI 0.67–1.30, I2=65%; p=0.670) 
(Fig. 4B) and for pT2 tumors in studies published after 2010 (7 
studies with 2321 patients; RR 0.73, 95% CI 0.45–1.19, I2=73%; 
p=0.210) to determine the effect of removing any outliers. How-
ever, there was still moderate heterogeneity (Fig. 4C). 
Biochemical recurrence
Fourteen studies (8259 participants) reported recurrence of 
prostate cancer, defined at various cut-off values of >0.4 ng/mL, 
>0.2 ng/mL, ≥2 ng/mL, >0.1 ng/mL, or ≥0.1 ng/mL. Therefore, 
the subgroup analysis was performed according to definition 
of PSA failure. Rates of BCR were reported in five studies (1485 
participants) using the definition PSA level >0.2 ng/mL.17-21 
RARP was associated with a reduced risk of BCR, compared to 
RRP (RR 0.71, 95% CI 0.61–0.81, I2=0%; p<0.001) (Fig. 5A). Sub-
group analysis according to follow-up duration demonstrated 
a similar recurrence-free survival between the two procedures 
upon long-term follow up (Fig. 5B).
Publication bias
Publication bias for each outcome was tested using Egger’s re-
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gression test, and showed only one example of publication bias 
associated with reported transfusion rates (Supplementary 
Table 4, only online). So, trill and fill analysis was performed 
to adjust the publication bias. After excluding eight studies by 
trim-and-fill analysis, the risk ratio of transfusion rate was still 
lower in RARP than in RRP (RR 0.26, 95% CI 0.17–0.38). 
DISCUSSION
To explore the supposed superiority of robotic platforms in 
treating prostate cancer, we performed a systematic review of 
all research published to 2013 that compared RARP with RRP. 
We found no randomized controlled study in which the two 
modalities were compared. Thus, we included only 61 non-
randomized studies, of which 20 were prospective and 41 were 
retrospective. Studies were regarded as being of high quality if 
three of four domains (random sequence generation, con-
founding, blinding, and incomplete outcome reporting) were 
judged to have a low risk of bias. Only 13 (21.3%) publications 
met these criteria, and the risk of bias in most of the studies 
might confound the true effects of RARP. 
Since 2010, 23 systematic reviews have been published, and 
they reported various outcomes. Our systematic review in-
cluded recently published studies and reflects comprehensive 
primary outcomes, including perioperative outcomes, func-
RARP RRP Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI Year M-H, random, 95% CI
Ham, et al.50 109 188 33 110 12.8% 1.93 [1.42, 2.64] 2008
Krambeck, et al.53 174 248 309 492 18.8% 1.12 [1.00, 1.24] 2009
Ficarra, et al.69 52 64 20 41 12.1% 1.67 [1.19, 2.33] 2009
Nadler, et al.58 8 22 0 4 0.5% 3.70 [0.25, 54.07] 2010
Rocco, et al.25 48 79 88 215 15.0% 1.48 [1.17, 1.89] 2009
Ou, et al.19 14 16 1 2 1.6% 1.75 [0.43, 7.08] 2009
Hohwü, et al.35 31 77 68 154 12.4% 0.91 [0.66, 1.26] 2011
Di Pierro, et al.47 12 22 12 47 6.2% 2.14 [1.15, 3.97] 2011
Ludovico, et al.56 22 60 12 48 6.6% 1.47 [0.81, 2.65] 2013
Choo, et al.45 42 77 70 176 14.0% 1.37 [1.04, 1.80] 2013
Total (95% CI) 853 1289 100.0% 1.41 [1.18, 1.70]
Total events 512 613
Heterogeneity: tau2=0.04; chi2=25.78, df=9 (p=0.002); I²=65%
Test for overall effect: Z=3.67 (p=0.0002)
Fig. 3. Functional outcomes: RARP vs. RRP.  (A) Incontinence rate at 12 months after surgery. (B) Potency rate at 12 months after surgery. RARP,  robot-as-
sisted radical prostatectomy; RRP, retropubic radical prostatectomy; CI, confidence interval.
0.01                0.1                  1                    10              100
0.02             0.1                     1                       10             50
Favours RARP
Favours RRP
Favours RRP
Favours RARP
RARP RRP Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI Year M-H, random, 95% CI
Ham, et al.50 15 188 20 110 14.2% 0.44 [0.23, 0.82] 2008
Nadler, et al.58 5 44 5 46 7.6% 1.05 [0.32, 3.36] 2010
Ou, et al.19 0 30 1 30 1.5% 0.33 [0.01, 7.87] 2009
Rocco, et al.25 2 79 26 217 5.8% 0.21 [0.05, 0.87] 2009
Ficarra, et al.69 6 103 17 105 10.5% 0.36 [0.15, 0.88] 2009
Krambeck, et al.53 20 244 30 476 15.5% 1.30 [0.75, 2.24] 2009
Di Pierro, et al.47 5 45 15 75 9.8% 0.56 [0.22, 1.43] 2011
Hohwü, et al.35 10 77 46 154 14.2% 0.43 [0.23, 0.81] 2011
Iseki, et al.34 5 44 15 60 9.9% 0.45 [0.18, 1.16] 2012
Ludovico, et al.56 4 82 1 48 2.9% 2.34 [0.27, 20.35] 2013
Choo, et al.45 5 77 7 176 8.1% 1.63 [0.53, 4.98] 2013
Total (95% CI) 1013 1497 100.0% 0.62 [0.42, 0.93]
Total events 77 183
Heterogeneity: tau2=0.19; chi2=18.96, df=10 (p=0.04); I2=47%
Test for overall effect: Z=2.34 (p=0.02)
A
B
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Fig. 4. Positive margin rate: RARP vs. RRP. (A) Positive margin rate. RARP,  robot-assisted radical prostatectomy; RRP, retropubic radical prostatectomy; CI, 
confidence interval.
 0.2              0.5          1             2                5
Favours RARP Favours RRP
RARP RRP Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI Year M-H, random, 95% CI
1) Prospective cohort study
Tewari, et al.17 18 200 23 100 2.5% 0.39 [0.22, 0.69] 2003
Wood, et al.68 21 117 8 89 1.8% 2.00 [0.93, 4.30] 2007
Ham, et al.50 37 118 29 110 3.2% 1.19 [0.79, 1.79] 2008
Fracalanza, et al.26 10 35 6 26 1.5% 1.24 [0.52, 2.97] 2008
Ficarra, et al.69 35 103 21 105 2.9% 1.70 [1.06, 2.71] 2009
Kordan, et al.52 171 830 132 414 4.1% 0.65 [0.53, 0.78] 2010
Loeb, et al.21 22 152 25 137 2.7% 0.79 [0.47, 1.34] 2010
Doumerc, et al.48 45 212 84 502 3.6% 1.27 [0.92, 1.75] 2010
Breyer, et al.44 54 292 108 695 3.7% 1.19 [0.88, 1.60] 2010
Kim, et al.70 143 528 58 235 3.8% 1.10 [0.84, 1.43] 2011
Di Pierro, et al.47 11 74 23 72 2.2% 0.47 [0.25, 0.88] 2011
Williams, et al.67 80 604 30 346 3.2% 1.53 [1.03, 2.27] 2010
Ludovico, et al.56 8 82 14 48 1.7% 0.33 [0.15, 0.74] 2013
Subtotal (95% CI) 3347 2879 37.0% 0.95 [0.74, 1.23]
Total events 655 561
Heterogeneity: tau²=0.16; chi²=59.36, df=12 (p<0.00001); I²=80%
Test for overall effect: Z=0.36 (p=0.72)
2) Retrospective cohort study
Ahlering, et al.43 10 60 12 60 1.8% 0.83 [0.39, 1.78] 2004
Smith, et al.63 30 199 69 197 3.3% 0.43 [0.29, 0.63] 2007
Schroeck, et al.61 106 362 122 435 4.0% 1.04 [0.84, 1.30] 2008
Laurila, et al.54 11 88 12 84 1.8% 0.88 [0.41, 1.87] 2009
Coronato, et al.46 12 98 14 57 2.0% 0.50 [0.25, 1.00] 2009
Rocco, et al.25 26 120 60 240 3.2% 0.87 [0.58, 1.30] 2009
Ou, et al.19 15 30 6 30 1.7% 2.50 [1.12, 5.56] 2009
Drouin, et al.18 12 71 15 83 2.1% 0.94 [0.47, 1.86] 2009
White, et al.66 11 50 18 50 2.2% 0.61 [0.32, 1.16] 2009
Nadler, et al.58 5 50 12 50 1.3% 0.42 [0.16, 1.10] 2010
Krambeck, et al.53 46 294 100 588 3.6% 0.92 [0.67, 1.27] 2009
Barocas, et al.20 281 1413 148 491 4.2% 0.66 [0.56, 0.78] 2010
Lo, et al.55 4 20 5 20 1.0% 0.80 [0.25, 2.55] 2010
Uvin, et al.64 1 13 0 9 0.2% 2.14 [0.10, 47.38] 2010
Magheli, et al.57 102 522 75 522 3.8% 1.36 [1.04, 1.79] 2011
Philippou, et al.59 9 50 10 50 1.7% 0.90 [0.40, 2.02] 2012
Hong, et al.51 52 182 46 80 3.7% 0.50 [0.37, 0.67] 2012
Wang, et al.65 160 1038 95 707 4.0% 1.15 [0.91, 1.45] 2012
Punnen, et al.60 68 233 40 177 3.5% 1.29 [0.92, 1.81] 2013
Iseki, et al.34 17 44 23 60 2.8% 1.01 [0.62, 1.65] 2012
Froehner, et al.49 33 252 242 1925 3.5% 1.04 [0.74, 1.46] 2013
Silberstein, et al.62 74 493 147 691 3.9% 0.98 [0.76, 1.27] 2013
Choo, et al.45 30 77 70 178 3.5% 0.99 [0.71, 1.38] 2013
Subtotal (95% CI) 5759 7054 63.0% 0.88 [0.75, 1.03]
Total events 1115 1341
Heterogeneity: tau²=0.09; chi²=76.49, df=22 (p<0.00001); I²=71%
Test for overall effect: Z=1.58 (p=0.11)
Total (95% CI) 9106 9933 100.0% 0.91 [0.79, 1.04]
Total events 1770 1902
Heterogeneity: tau²=0.10; chi²=136.83, df=35 (p<0.00001); I²=74%
Test for overall effect: Z=1.41 (p=0.16) 
Test for subgroup differences: chi²=0.28, df=1 (p=0.60); I²=0%
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tional outcomes, and oncologic outcomes. Compared to open 
surgery, RARP yielded superior outcomes in terms of compli-
cations, such as organ injury, pulmonary embolism, and 
bladder neck contracture. In addition, the risk of overall com-
plications assessed using the Clavien-Dindo classification was 
lower for RARP than RRP, although a high level of study het-
erogeneity was evident. Notably, the risk of complications af-
ter RARP was significantly lower than that after RRP, unlike 
earlier reports.7,11 Our findings are in line with results reported 
elsewhere. That is, a population-based observational cohort 
study using US Surveillance, Epidemiology, and End Results 
Medicare-linked data found that minimally invasive radical 
prostatectomy with or without robotic assistance was associ-
ated with lower rates of postoperative respiratory complica-
tions (4.3% vs. 6.6%; p=0.004), miscellaneous surgical compli-
cations (4.3% vs. 5.6%; p=0.03), and anastomotic stricture 
(5.8% vs. 14.0%; p<0.001), compared to RRP.22 In addition, 
RARP postoperative courses based on claims made to the South 
Korean Health Insurance Review and Assessment Service 
from September 2005 to December 2011 might be lower than 
RRP. Totals of 1830 and 1660 patients underwent RARP and 
RRP, respectively, and postoperative complication rates to 30 
days as measured by re-admission to intensive care units were 
0.1% and 0.2%, respectively.23 Thus, we suggest that RARP can 
be performed with a reasonably low complication rate.
In the present study, RARP was associated with better peri-
operative outcomes than RRP in terms of operation time and 
length of hospital stay, consistent with findings of previous sys-
tematic reviews and meta-analyses.7,24 In addition, claims data 
from South Korea showed that RARP-associated hospital stays 
were shorter than those for RRP (RARP 9 days vs. RRP 12.7 
days). We sought to explore heterogeneity in pooled estimates 
of operative time by performing subgroup analysis according 
to the definition of operative time, but could not do so because 
most studies did not describe how they measured the dura-
tion of surgery. Only four studies reported durations of sur-
gery as follows: from skin incision to skin closure time in both 
procedures;25 from insertion of the Veress needle (RARP) to the 
suture of the last laparoscopic port, and skin incision to suture 
(RRP);26 as the time from incision to placement of dressings;27 
0.01              0.1                  1                  10             100
0.02          0.1                     1                      10            50
Favours RRP
Favours RRP
Favours RARP
Favours RARP
RARP RRP Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI Year M-H, random, 95% CI
Rocco, et al.25 26 120 60 240 17.3% 0.87 [0.58, 1.30] 2009
Ficarra, et al.69 35 103 21 105 16.0% 1.70 [1.06, 2.71] 2009
White, et al.66 11 50 18 50 12.5% 0.61 [0.32, 1.16] 2009
Philippou, et al.59 9 50 10 50 9.8% 0.90 [0.40, 2.02] 2012
Iseki, et al.34 17 44 23 60 15.5% 1.01 [0.62, 1.65] 2012
Punnen, et al.60 68 233 40 177 18.8% 1.29 [0.92, 1.81] 2013
Ludovico, et al.56 8 82 14 48 10.1% 0.33 [0.15, 0.74] 2013
Total (95% CI) 682 730 100.0% 0.93 [0.67, 1.30]
Total events 174 186
Heterogeneity: tau²=0.12; chi²=17.23, df=6 (p=0.008); I²=65%
Test for overall effect: Z=0.43 (p=0.67)
RARP RRP Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI Year M-H, random, 95% CI
Nadler, et al.58 2 46 3 33 5.8% 0.51 [0.09, 2.89] 2010
Doumerc, et al.48 17 146 13 54 16.0% 0.48 [0.25, 0.93] 2010
Di Pierro, et al.47 5 60 13 54 11.9% 0.35 [0.13, 0.91] 2011
Magheli, et al.57 36 387 24 364 18.2% 1.41 [0.86, 2.32] 2011
Hong, et al.51 35 148 30 61 19.8% 0.48 [0.33, 0.71] 2012
Philippou, et al.59 5 32 4 27 9.3% 1.05 [0.31, 3.54] 2012
Silberstein, et al.62 31 315 46 597 19.1% 1.28 [0.83, 1.97] 2013
Subtotal (95% CI) 1131 1190 100.0% 0.73 [0.45, 1.19]
Total events 131 133
Heterogeneity: tau²=0.27; chi²=22.16, df=6 (p=0.001); I²=73%
Test for overall effect: Z=1.27 (p=0.21)
Fig. 4. Positive margin rate: RARP vs. RRP. (B) Positive margin rate of studies assessed as low risk studies. (C) Positive margin rate for pT2 tumors in studies 
published after 2010. RARP,  robot-assisted radical prostatectomy; RRP, retropubic radical prostatectomy; CI, confidence interval.
B
C
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Fig. 5. Biochemical recurrence: RARP vs. RRP. (A) Biochemical recurrence according to definition of PSA failure. RARP,  robot-assisted radical prostatecto-
my; RRP, retropubic radical prostatectomy; CI, confidence interval.
0.05          0.2               1                 5             20
Favours RARP Favours RRP
RARP RRP Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI Year M-H, random, 95% CI
1) PSA >0.4 ng/mL
Krambeck, et al.53 14 248 32 492 7.8% 0.87 [0.47, 1.60] 2009
Subtotal (95% CI) 248 492 7.8% 0.87 [0.47, 1.60]
Total events 14 32
Heterogeneity: not applicable
Test for overall effect: Z=0.46 (p=0.65)
2) PSA >0.2 ng/mL
Tewari, et al.17 16 200 15 100 7.3% 0.53 [0.28, 1.03] 2003
Drouin, et al.18 7 71 12 83 5.5% 0.68 [0.28, 1.64] 2009
Ou, et al.19 6 30 5 30 4.3% 1.20 [0.41, 3.51] 2009
Barocas, et al.20 181 425 155 257 12.1% 0.71 [0.61, 0.82] 2010
Loeb, et al.21 7 152 7 137 4.6% 0.90 [0.32, 2.50] 2010
Subtotal (95% CI) 878 607 33.8% 0.71 [0.61, 0.81]
Total events 217 194
Heterogeneity: tau²=0.00; chi²=1.85, df=4 (p=0.76); I²=0%
Test for overall effect: Z=4.86 (p<0.00001)
3) PSA ≥2 ng/mL
Schroeck, et al.61 29 362 54 435 9.6% 0.65 [0.42, 0.99] 2008
Hohwü, et al.35 4 77 21 154 4.5% 0.38 [0.14, 1.07] 2011
Punnen, et al.60 79 233 57 177 11.1% 1.05 [0.80, 1.39] 2013
Choo, et al.45 5 77 23 176 5.1% 0.50 [0.20, 1.26] 2013
Subtotal (95% CI) 749 942 30.4% 0.70 [0.44, 1.10]
Total events 117 155
Heterogeneity: tau²=0.12; chi²=7.78, df=3 (p=0.05); I²=61%
Test for overall effect: Z=1.56 (p=0.12)
4) PSA >0.1 or PSA ≥0.1 ng/mL
Nadler, et al.58 4 50 3 50 2.8% 1.33 [0.31, 5.65] 2010
Silberstein, et al.62 16 493 39 961 8.1% 0.80 [0.45, 1.42] 2013
Subtotal (95% CI) 543 1011 10.9% 0.86 [0.50, 1.46]
Total events 20 42
Heterogeneity: tau²=0.00; chi²=0.42, df=1 (p=0.52); I²=0%
Test for overall effect: Z=0.57 (p=0.57)
5) Not reported
Magheli, et al.57 28 522 17 522 8.0% 1.65 [0.91, 2.97] 2011
Wang, et al.65 21 1038 70 707 9.1% 0.20 [0.13, 0.33] 2012
Subtotal (95% CI) 1560 1229 17.1% 0.58 [0.07, 4.46]
Total events 49 87
Heterogeneity: tau²=2.11; chi²=29.04, df=1 (p<0.00001); I²=97%
Test for overall effect: Z=0.53 (p=0.60)
Total (95% CI) 3978 4281 100.0% 0.71 [0.54, 0.93]
Total events 417 510
Heterogeneity: tau²=0.16; chi²=47.23, df=13 (p<0.00001); I²=72%
Test for overall effect: Z=2.49 (p=0.01)
Test for subgroup differences: chi²=0.91, df=4 (p=0.92); I²=0%
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and as the mean operative time of hernia repair.28
Our results are comparable with those of a propensity-score 
matching study that adjusted for among-series differences in 
preoperative Gleason scores, preoperative PSA levels, and 
pathological stages. The cited work comprised a systematic 
review and meta-analysis of RRP, laparoscopic radical prosta-
tectomy, and RARP patient series, and found that the rate of 
perioperative complications was significantly lower for RARP 
than RRP.24
The prevalence of urinary incontinence and erectile dysfunc-
tion after RARP are affected by preoperative patient charac-
teristics (age, body mass index, and comorbidities), the expe-
rience of the surgeon, the surgical technique used, and me-
thodological features, such as the definitions of continence and 
Fig. 5. Biochemical recurrence: RARP vs. RRP. (B) Biochemical recurrence according to follow-up duration. RARP, robot-assisted radical prostatectomy; 
RRP, retropubic radical prostatectomy; CI, confidence interval.
0.005                 0.1               1                10                 200
Favours RARP Favours RRP
RARP RRP Risk ratio Risk ratio
Study or subgroup Events Total Events Total Weight M-H, random, 95% CI Year M-H, random, 95% CI
1) Follow-up duration ≤1 yr
Hohwü, et al.35 4 77 21 154 4.5% 0.38 [0.14, 1.07] 2011
Wang, et al.65 21 1038 70 707 9.1% 0.20 [0.13, 0.33] 2012
Subtotal (95% CI) 1115 861 13.6% 0.23 [0.14, 0.39]
Total events 25 91
Heterogeneity: tau²=0.03; chi²=1.15, df=1 (p=0.28); I²=13%
Test for overall effect: Z=5.64 (p<0.00001)
2) 1<Follow-up duration≤2 yrs
Tewari, et al.17 16 200 15 100 7.3% 0.53 [0.28, 1.03] 2003
Schroeck, et al.61 29 362 54 435 9.6% 0.65 [0.42, 0.99] 2008
Ou, et al.19 6 30 5 30 4.3% 1.20 [0.41, 3.51] 2009
Krambeck, et al.53 14 248 32 492 7.8% 0.87 [0.47, 1.60] 2009
Magheli, et al.57 28 522 17 522 8.0% 1.65 [0.91, 2.97] 2011
Silberstein, et al.62 16 493 39 961 8.1% 0.80 [0.45, 1.42] 2013
Choo, et al.45 5 77 23 176 5.1% 0.50 [0.20, 1.26] 2013
Subtotal (95% CI) 1932 2716 50.2% 0.81 [0.59, 1.10]
Total events 114 185
Heterogeneity: tau²=0.07; chi²=9.78, df=6 (p=0.13); I²=39%
Test for overall effect: Z=1.34 (p=0.18)
3) More than 2 yrs follow-up
Nadler, et al.58 4 50 3 50 2.8% 1.33 [0.31, 5.65] 2010
Drouin, et al.18 7 71 12 83 5.5% 0.68 [0.28, 1.64] 2009
Barocas, et al.20 181 425 155 257 12.1% 0.71 [0.61, 0.82] 2010
Punnen, et al.60 79 233 57 177 11.1% 1.05 [0.80, 1.39] 2013
Subtotal (95% CI) 779 567 31.6% 0.84 [0.62, 1.14]
Total events 271 227
Heterogeneity: tau²=0.04; chi²=6.95, df=3 (p=0.07); I²=57%
Test for overall effect: Z=1.12 (p=0.26)
4) Not reported
Loeb, et al.21 7 152 7 137 4.6% 0.90 [0.32, 2.50] 2010
Subtotal (95% CI) 152 137 4.6% 0.90 [0.32, 2.50]
Total events 7 7
Heterogeneity: not applicable
Test for overall effect: Z=0.20 (p=0.84)
Total (95% CI) 3978 4281 100.0% 0.71 [0.54, 0.93]
Total events 417 510
Heterogeneity: tau²=0.16; chi²=47.23, df=13 (p<0.00001); I²=72%
Test for overall effect: Z=2.49 (p=0.01)
Test for subgroup differences: chi²=20.44, df=3 (p=0.0001); I²=85.3%
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potency, outcome measures, and follow-up periods.29 To opti-
mize our evaluation of functional outcomes, we included only 
outcome data obtained using objective measures or reliable 
and valid measurement instruments. In detail, the definition 
of continence was the use of no pad at all, 0–1 pads per day, or 
no leak measured by a validated questionnaire including the 
International Consultation of Incontinence Questionnaire-
Urinary Incontinence; and that for erectile function a positive 
response to a validated questionnaire reporting erection suffi-
cient for intercourse with or without prescription of a phos-
phodiesterase type 5 inhibitor or a score >17 on the Sexual 
Health Inventory for Men or 5-item version of the International 
Index of Erectile Function validated questionnaires exploring 
erectile dysfunction. 
In this review, urinary incontinence and erectile function 
recovery rates measured at 12 months after RARP were lower 
than those after RRP. Our findings suggest positive functional 
outcomes of RARP, because of an increase of magnitude in ef-
fect size, compared to previous systematic review.11 The bene-
ficial effects on the functional outcomes of RARP, compared 
to RRP, remained even in meta-analysis that added the study 
findings recently reported by Haglind, et al.30 [incontinence 
rate: 12 studies, 4937 participants, RR (M-H, random) 0.68, 95% 
CI 0.47–0.98, I2=62%; potency rate: 11 studies, 4564 partici-
pants, RR (M-H, random) 1.36, 95% CI 1.18–1.57, I2=61%].
The positive effect of functional outcomes of RARP is attrib-
utable to developments in surgical technique: nerve sparing 
improves both continence and potency, because the urethral 
rhabdosphincter receives afferent fibers from the traversing 
bundle.31 On robotic platforms, three-dimensional-magnified 
views allow meticulous dissection of both the periprostatic fas-
cia layer and the neurovascular bundle. New insights into the 
multilayer structure of the periprostatic fascia and the course 
of the cavernous nerves have supported the development of 
intra- or inter-fascial surgical planes, enabling the urinary and 
sexual functional outcomes to be improved. Developments in 
RARP operative techniques improving urinary function, such 
as puboprostatic-sparing approaches, bladder neck preserva-
tion, selective dorsal vein complex division, nerve-sparing 
mechanisms, reconstruction of the posterior musculofascia, 
and anterior restoration of the pelvic space, are advocated. 
Meanwhile, several physician-reported studies showed incon-
tinence rates ranging from 10 to 15% at 12 months after radical 
prostatectomy.32,33 Considering that an acceptable inconti-
nence rate is about 10%, regardless of the surgical technique, 
two studies included in this review might be performed by 
under-experienced surgeons due to a high incontinence rate, 
reaching 25 to 30%.34,35 Urinary incontinence and erectile dys-
function are highly problematic conditions affecting many as-
pects of quality of life, and healthcare providers must be aware 
of this.36-38 Although a randomized controlled study was not 
included in this review, our results suggest that healthcare 
providers should consider patient preferences in terms of re-
covery of urinary and erectile function when choosing be-
tween RARP and RRP, even though disparities in the receipt of 
RARP in terms of demographic characteristics, such as house-
hold income and insurance status, were reported.39
The rate of positive surgical margins was comparable be-
tween RARP and RRP (RR 0.95, 95% CI 0.74–1.23, I2=80%). In 
sensitivity analysis to explore the heterogeneity, our results 
did not change in the analysis restricted to studies rated as low 
risk of bias and for pT2 tumors studies published after 2010. 
The results were consistent with the findings of previous sys-
tematic reviews.22 Pooled estimates from 15 studies published 
from 2004 to 2011 showed that RARP is associated with a lower 
rate of positive surgical margins for pT2 tumors (RR 0.63, 95% 
CI 0.49–0.81, I2=27.7%).5 However, we suggest that our find-
ings reflect more recent evidence of the comparative effective-
ness of RARP versus RRP. Furthermore, this result was consis-
tent with the recent cohort study investigating long-term 
oncologic outcomes, including positive surgical margins, in 
RARP compared to RRP (between group comparison p=0.230).40
In the present review, RARP was associated with a lower 
rate of BCR, compared to RRP, regardless of the manner in 
which such recurrence was defined (14 studies with 8259 pa-
tients; RR 0.71, 95% CI 0.54–0.93, I2=72%). To explore the effect 
of heterogeneity, we classified studies in terms of their defini-
tion of PSA failure, and selected PSA >0.2 ng/mL as an optimal 
criterion based on clinical practice guidelines.41 Upon sub-
group analysis, RARP was superior to RRP in this context (five 
studies with 1485 patients; RR 0.71, 95% CI 0.61–0.81, I2=0%); 
heterogeneity was not an issue in this subgroup. This result is 
inconsistent with that of an earlier meta-analysis (hazard ratio 
0.9, 95% CI 0.7–1.2, p=0.526), which reported differences in 
the definition of BCR-free survival.42 In additional analysis ac-
cording to follow-up period, PSA failure rates were signifi-
cantly lower in RARP than in RRP in a short term follow-up of 
1 year or less. However, PSA failure rates between the two pro-
cedures were similar in long-term follow up. 
Our present review had several limitations. First, significant 
oncologic and functional heterogeneity was evident; surgical 
skills and experience vary. Second, no randomized controlled 
trial has been conducted. Third, virtually no significant report 
on cancer-specific mortality rate following RARP has been pub-
lished, because of the long follow-up needed in prognostic 
studies on clinically localized prostate cancer and the fact that 
RARP is a relatively new procedure. 
In conclusion, we found that RARP might be favorable to RRP 
in aspects of post-operative complications, peri-operative out-
comes, and functional outcomes, including urinary and erec-
tile function. Also oncologic outcomes, such as positive mar-
gins and BCR, were comparable between two groups. However, 
most included studies were non-randomized studies and mod-
erate to substantial heterogeneity was evident. Therefore, we 
suggest that further high quality studies minimizing selection, 
confounding, and selective reporting biases with longer-term 
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follow-up are needed to determine clinical efficacy and safety 
of RARP.
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